Results 11 to 20 of about 154,825 (291)

Primary extranodal diffuse large B‐cell lymphoma: Molecular features, treatment, and prognosis

Aging and Cancer, Volume 3, Issue 3-4, Page 133-146, September-December 2022., 2022
One‐third of DLBCL arises from extranodal organs and is challenging to manage. Molecular features are critical to elucidate the differences in clinical features, predict the disease prognosis, and improve effective targeted therapeutic strategies. Abstract Diffuse large B‐cell lymphoma (DLBCL) is the most common subtype of non‐Hodgkin's lymphoma and ...
Si‐Yuan Chen, Meng‐Meng Ji, Peng‐Peng Xu, Wei‐Li Zhao   +3 more
wiley   +1 more source

Brain magnetic resonance imaging predictors in anti‐N‐methyl‐D‐aspartate receptor encephalitis

Annals of Clinical and Translational Neurology, Volume 9, Issue 12, Page 1974-1984, December 2022., 2022
Abstract Objective Brain magnetic resonance imaging (MRI) findings in anti‐N‐methyl‐D‐aspartate receptor (NMDAR) encephalitis are nonspecific and rarely have obvious associations with clinical characteristics and outcomes. This study aimed to comprehensively describe the MRI features of patients with NMDAR encephalitis, examine their associations with ...
Ying‐Ying Zhao, Bing Han, Cui‐Hong Qin, Xue‐Xiu Shi, Wen‐Jing Yun, Meng Wang, Bo Yuan, Tong‐Wen Sun, Hai‐Xu Wang   +8 more
wiley   +1 more source

Cyclophosphamide alters the gene expression profile in patients treated with high doses prior to stem cell transplantation. [PDF]

PLoS ONE, 2014
BACKGROUND: Hematopoietic stem cell transplantation is a curative treatment for several haematological malignancies. However, treatment related morbidity and mortality still is a limiting factor.
Ibrahim El-Serafi, Manuchehr Abedi-Valugerdi, Zuzana Potácová, Parvaneh Afsharian, Jonas Mattsson, Ali Moshfegh, Moustapha Hassan   +6 more
doaj   +1 more source

Combining CD34+ stem cell selection with prophylactic pathogen and leukemia directed T‐cell immunotherapy to simultaneously reduce graft versus host disease, infection, and leukemia recurrence after allogeneic stem cell transplant

American Journal of Hematology, Volume 98, Issue 1, Page 159-165, January 2023., 2023
Donor stem cell product undergoes CD34 stem cell selection. CD34 positive stem cells are used for transplantation. Pathogen‐ and leukemia‐specific T‐cells are manufactured from CD34 negative fraction and infused prophylactically 21 days after transplant.
David J. Gottlieb, Gaurav Sutrave, Wei Jiang, Selmir Avdic, Janine A. Street, Renee Simms, Leighton E. Clancy, Vicki Antonenas, Brian S. Gloss, Caroline Bateman, David C. Bishop, Kenneth P. Micklethwaite, Emily Blyth   +12 more
wiley   +1 more source

Cognitive impairment and elevated peripheral cytokines in breast cancer patients receiving chemotherapy

Arquivos de Neuro-Psiquiatria, 2022
Background Anthracyclines-based regimen (5-fluorouracil, doxorubicin, and cyclophosphamide (FAC); cyclophosphamide, epirubicin, and 5-fluorouracil [CEF]) and non-anthracycline based regimens (cyclophosphamide, methotrexate, and 5-fluorouracil [
Mohd Ashif Khan, Dinesh Bhurani, Ubedul Hoda, Nouroz Sehar, Nidhi Agarwal   +4 more
doaj   +1 more source

Cutaneous T‐cell lymphomas: 2023 update on diagnosis, risk‐stratification, and management

American Journal of Hematology, Volume 98, Issue 1, Page 193-209, January 2023., 2023
Abstract Disease Overview Cutaneous T‐cell lymphomas are a heterogenous group of T‐cell neoplasms involving the skin, the majority of which may be classified as Mycosis Fungoides (MF) or Sézary Syndrome (SS). Diagnosis The diagnosis of MF or SS requires the integration of clinical and histopathologic data.
Alexandra C. Hristov, Trilokraj Tejasvi, Ryan A. Wilcox   +2 more
wiley   +1 more source

Platelet Augmentation Potential of Polyherbal Formulation in Cyclophosphamide-Induced Thrombocytopenia in Wistar Rats [PDF]

Folia Medica, 2021
Introduction: Thrombocytopenia is a condition characterized by abnormally low levels of thrombocytes, also known as platelets, in the blood. Several medicinal plants possess curative and protective effect against thrombocytopenia associated with diseases
Girish Sailor, Komal Hirani, Ghanshyam Parmar, Rajesh Maheshwari, Rupa Singh, Avinash Kumar Seth   +5 more
doaj   +3 more sources

Metabolism of cyclophosphamide [PDF]

Cancer, 1967
The in vivo activation of cyclophosphamide (Endoxan) to cytostatic and alkylating metabolites has been studied. Endoxan is metabolized to the weak anion by microsomal dealkylation in the rat's liver; this product is the first alkylating metabolite.
N. Brock, H.-J. Hohorst
openaire   +3 more sources

Utilization of real‐world data in assessing treatment effectiveness for diffuse large B‐cell lymphoma

American Journal of Hematology, Volume 98, Issue 1, Page 180-192, January 2023., 2023
Abstract Direct comparisons of the effectiveness of the numerous novel therapies in the diffuse large B‐cell lymphoma (DLBCL) treatment landscape in a range of head‐to‐head randomized phase 3 trials would be time‐consuming and costly. Comparative effectiveness studies using real‐world data (RWD) represent a complementary approach.
Grzegorz Nowakowski, Matthew J. Maurer, James R. Cerhan, Debarshi Dey, Laurie H. Sehn   +4 more
wiley   +1 more source

Tumors That Acquire Resistance to Low-Dose Metronomic Cyclophosphamide Retain Sensitivity to Maximum Tolerated Dose Cyclophosphamide

Neoplasia: An International Journal for Oncology Research, 2011
Low-dose metronomic (LDM) chemotherapy is emerging as an alternative or supplemental dosing strategy to conventional maximum tolerated dose (MTD) chemotherapy. It is characterized primarily, but not exclusively, by antiangiogenic mechanisms of action and
Urban Emmenegger, Giulio Francia, Annabelle Chow, Yuval Shaked, Andrew Kouri, Shan Man, Robert S. Kerbel   +6 more
doaj   +1 more source